Zimbabwe Pharmaceutical Market - Growth, Trends, COVID-19 Impact and Forecast (2022 - 2027)

The Zimbabwe Pharmaceutical Market is Segmented by ATC/Therapeutic Category (Blood and Hematopoietic Organs, Digestive Organ and Metabolism, Cardiovascular System, Nervous System, Musculoskeletal Organ, General Anti-infectives Systemic, Respiratory System, and Other ATC/Therapeutic Categories) and Drug Type (Prescription Drugs (Rx) (Branded and Generic), and OTC Drugs). The report offers the value (USD million) for the above segments.

Market Snapshot

Zimbabwe Pharmaceutical Market Size
Study Period: 2019-2027
Base Year: 2021
CAGR: 4.35 %
Zimbabwe Pharmaceutical Market key players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The pharmaceutical market in Zimbabwe is expected to register a CAGR of 4.35% over the forecast period (2022-2027).

The COVID-19 impact on the pharmaceutical industry in Zimbabwe was significant. The industry saw an increased demand for therapeutics to treat COVID-19-infected patients, which further led to an increase in the large-scale manufacturing of pharmaceutical products in the country. However, the supply chain between the other regions of the world and Zimbabwe was disrupted due to lockdown measures. Thus, local manufacturers played a critical role during the COVID-19 pandemic. According to a research article titled "Impact of COVID-19 on Supply Chains in Zimbabwe", published in the Journal of Public health International in May 2021, the disruption of medical supplies such as pharmaceuticals during the pandemic provided a great opportunity for Zimbabwe to be less dependent on the foreign medical supplies, thereby increasing the local manufacturing of therapeutics.

The Zimbabwean Ministry of Health and ChildCare (MOHCC) has taken measures to strengthen the country's ability to produce medical supplies through various organizations such as Varichem, CAPS, Natpharma, and Avail Pharmaceuticals during the pandemic. Thus, the abovementioned factors are expected to significantly impact the market’s growth.

The Zimbabwean pharmaceutical market is expected to grow due to the growing burden of the geriatric population and the increasing incidence of chronic diseases. According to the United Nations’ World Population Ageing Report 2019, the population aged 65 years and above in Zimbabwe was estimated at 437,000 in 2019. It is expected to reach 585,000 by 2030. As the growing elderly population is more prone to chronic diseases such as cardiovascular diseases, cancers, and gastrointestinal disorders, the demand for effective and novel therapeutics is expected to grow in the coming years. Thus, the abovementioned factors are anticipated to aid the market's growth over the forecast period. However, the stringent regulatory framework is expected to restrain the growth.

Scope of the Report

As per the scope of the report, pharmaceuticals are referred to as prescribed and non-prescription drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor’s consent. The Zimbabwean pharmaceutical market is segmented by ATC/therapeutic category and drug type. The report offers the value (USD million) for the abovementioned segments.

By ATC/Therapeutic Category
Blood and Hematopoietic Organs
Digestive Organ and Metabolism
Cardiovascular System
Nervous System
Musculoskeletal Organ
General Antiinfectives Systemic
Respiratory System
Other ATC/Therapeutic Categories
By Drug Type
Prescription Drugs (Rx)
OTC Drugs

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Prescription Drugs Segment Holds the Largest Share and is Expected to Continue the Trend During the Forecast Period

The prescription drugs segment in the Zimbabwean pharmaceutical market holds the largest share. It is expected to continue the trend during the forecast period. The major drivers are the increasing R&D activities by key players, the launch of new products aimed at treating various illnesses, the growing geriatric population, the rising prevalence of chronic diseases such as cardiovascular diseases, cancers, and autoimmune diseases, and the growing awareness about the use of prescription drugs in the country.

The prevalence of cardiovascular diseases, cancers, and other chronic diseases is increasing in Zimbabwe, thus boosting the demand for advanced therapeutics and driving the market. According to GLOBOCAN 2020, the incidence of cancers in Zimbabwe in 2020 was 16,083, and the mortality associated with cancers was 10,676. Rising cases of chronic diseases may lead to a rise in the use of prescription drugs, which may accelerate the demand in the country during the forecast period. The per capita healthcare expenditure in the country may also improve, further boosting the market’s growth during the forecast period.

In October 2021, The Medicines Control Authority of Zimbabwe approved three private hospitals and three private pharmacies to dispense Ivermectin, a broad-spectrum anti-parasitic drug for the prevention and treatment of COVID-19. Therefore, increasing approvals from the Government of Zimbabwe are expected to drive the growth of this segment.

Zimbabwe Pharmaceutical Market trends

Competitive Landscape

The Zimbabwean pharmaceutical market is highly competitive and consists of several major players. In terms of market share, a few major players are currently dominating the market. Some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some key companies are Datlabs, Pharmanova, CosPharma, Zim Laboratories, and B. Braun.

Recent Developments

  • In June 2021, the Zimbabwean government launched the 2021-2025 Pharmaceutical Manufacturing Strategy to improve the local production of drugs, thereby increasing the availability of the country's essential medicines and exporting the excess drugs.
  • In March 2021, the Republic of Zimbabwe became the 19thAfrican Union (AU) Member State to sign the Treaty to establish the African Medicines Agency (AMA). This move may enable a favorable regulatory environment for pharmaceutical research and development, local production, and trade across countries on the African continent.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

      1. 4.1.1 Healthcare Expenditure (Govt. vs Private)

      2. 4.1.2 Pharmaceutical Imports and Exports

      3. 4.1.3 Epidemiology Data for Key Diseases

      4. 4.1.4 Regulatory Landscape/Regulatory Bodies

      5. 4.1.5 Licensing and Market Authorization (Both Local Production and Imported Goods)

      6. 4.1.6 Pipeline Analysis

        1. By Phase

        2. By Sponsor

        3. By Disease

      7. 4.1.7 Statistical Overview

        1. Number of Hospitals

        2. Employment in Pharmaceutical Sector

        3. R&D Expenditure

      8. 4.1.8 Ease of Doing Business

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Geriatric Population

      2. 4.2.2 Increasing Incidence of Chronic Diseases

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By ATC/Therapeutic Category

      1. 5.1.1 Blood and Hematopoietic Organs

      2. 5.1.2 Digestive Organ and Metabolism

      3. 5.1.3 Cardiovascular System

      4. 5.1.4 Nervous System

      5. 5.1.5 Musculoskeletal Organ

      6. 5.1.6 General Antiinfectives Systemic

      7. 5.1.7 Respiratory System

      8. 5.1.8 Other ATC/Therapeutic Categories

    2. 5.2 By Drug Type

      1. 5.2.1 Prescription Drugs (Rx)

        1. Branded

        2. Generic

      2. 5.2.2 OTC Drugs


    1. 6.1 Company Profiles

      1. 6.1.1 Datlabs

      2. 6.1.2 Pharmanova

      3. 6.1.3 GlaxoSmithKline PLC

      4. 6.1.4 Zim Laboratories Limited

      5. 6.1.5 Nat Pharma

      6. 6.1.6 CosPharma

      7. 6.1.7 Viatris Inc.

      8. 6.1.8 Caps (Pvt) Ltd

      9. 6.1.9 B.braun

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Zimbabwe Pharmaceutical Market market is studied from 2019 - 2027.

The Zimbabwe Pharmaceutical Market is growing at a CAGR of 4.35% over the next 5 years.

Pharmanova, Zim Laboratories Limited, Datlabs, Caps (Pvt) Ltd, B. Braun are the major companies operating in Zimbabwe Pharmaceutical Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!